Abstract
In this study we analyzed the humoral immune response to glatiramer acetate in 16 GA-treated primary progressive MS patients and 9 placebo patients from the PROMiSe study. We have demonstrated that all multiple sclerosis patients (n=16) continuously treated with GA for 3 years developed anti-GA antibodies that peaked at month 3 and remained elevated during the whole study. We have also demonstrated that initially GA-reactive antibodies of the IgG1 subclass predominate, peaking at month 9 of therapy, but after 9 months IgG1 decreases while anti-GA antibodies of the IgG4 subclass increase and remain high for the 3 years of follow-up. These results support a shift from Th1 to Th2 in the antibody response to glatiramer acetate treatment.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Antibody Specificity
-
Cells, Cultured
-
Double-Blind Method
-
Female
-
Glatiramer Acetate
-
Humans
-
Immunoglobulin G / blood*
-
Immunosuppressive Agents / immunology
-
Immunosuppressive Agents / therapeutic use
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / immunology
-
Longitudinal Studies
-
Male
-
Multiple Sclerosis, Chronic Progressive / blood
-
Multiple Sclerosis, Chronic Progressive / drug therapy*
-
Multiple Sclerosis, Chronic Progressive / immunology*
-
Peptides / immunology*
-
Peptides / therapeutic use*
-
Th1 Cells / drug effects
-
Th1 Cells / immunology
-
Th2 Cells / drug effects
-
Th2 Cells / immunology
-
Time Factors
-
Up-Regulation / drug effects
-
Up-Regulation / immunology
Substances
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Peptides
-
Glatiramer Acetate